Our Approach

We uphold the highest standards of cellular care by ensuring every batch of our mesenchymal stem cells undergoes meticulous testing, from confirming essential MSC markers through flow cytometry to ensuring complete sterility and purity. Guided by global clinical research and Singapore’s commitment to precision and safety, our approach blends ethical sourcing, scientific rigor, and advanced regenerative insights to support your body with care that is both trustworthy and transformative.

Why Us

Every batch of our MSCs undergoes comprehensive testing to meet and exceed international safety and quality benchmarks. This includes:

  • Flow Cytometry Marker Confirmation: This test confirms the presence of specific markers (CD73+, CD90+, CD105+) that define MSCs.

  • Sterility Testing: This ensures the cells are free from mycoplasma and endotoxins.

Beyond these foundational assessments, our laboratory also performs viability checks to ensure the cells are healthy, active and capable of optimal function upon administration. We evaluate cell morphology, growth characteristics and population purity to maintain consistency across every batch. All testing is performed in controlled, accredited facilities following strict Good Manufacturing Practice standards, allowing us to deliver MSCs that are not only safe, but also reliable, potent and aligned with global clinical expectations.


Upholding the Highest Standards

This meticulous approach aligns with global clinical trends toward using human-origin, ethically processed MSCs for wellness and longevity support.

“Your body deserves cellular care held to the highest standards. That’s why we bring Singapore's clinical precision and safety to every session.” — Dr. Teo Cheng Peng, Medical Advisor, StemCord Therapeutics Inc.

Our sourcing practices are supported by a large body of peer-reviewed scientific studies. 

The following references demonstrate the safety and efficacy of our chosen approach:

  1. Caplan AI. (2017). Mesenchymal stem cells: Time to change the name. Nature Partner Journals – Regenerative Medicine.

  2. Dominici M, Le Blanc K, Mueller I, et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy.

  3. Squillaro T, Peluso G, Galderisi U. (2016). Clinical trials with mesenchymal stem cells: an update. Cell Transplantation / NIH PMC.

  4. Wang Y, Chen X, Cao W, Shi Y. (2018). Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Stem Cells International.

  5. Miao Z, Jin J, Chen L, et al. (2017). Safety and efficacy of human umbilical cord mesenchymal stem cells therapy for degenerative diseases. Oncotarget.

The Science Behind Our Approach